Immucell (ICCC) EBT Margin (2010 - 2026)
Immucell (ICCC) posted EBT Margin of 26.17% for Q2 2026, up 18.35 percentage points from 7.82% a year earlier.
Powered by 
Analysis
Immucell (ICCC) EBT Margin (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBT Margin at Immucell was -2.23%, down 8.50 percentage points year-over-year; for FY2025, it was -3.72%, up 4.38 percentage points from FY2024.
- Annual EBT Margin shows a five-year change of +3.01 percentage points (FY2020 to FY2025).
- In prior years, Immucell's EBT Margin was -8.10% in FY2024 (+24.92 pp), -33.02% in FY2023 (-19.64 pp), -13.39% in FY2022 (-13.03 pp) and -0.36% in FY2021 (+6.37 pp).
- The Q2 2026 figure stands as the highest quarterly EBT Margin since Q1 2015.
- On a year-over-year basis, EBT Margin increased in five of the last six quarters, with an average year-over-year change of +8.17 percentage points.
- The strongest year-over-year quarter for EBT Margin in the past five years was Q1 2024, with a gain of 61.11 percentage points; the weakest was Q1 2023, with a drop of 75.70 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,132.02 Bn | 1,100.60 Bn | 19.71 Bn | 40.25% |
| 2 | Johnson & Johnson | 613.16 Bn | 531.69 Bn | 17.26 Bn | 26.66% |
| 3 | AbbVie | 503.74 Bn | 476.85 Bn | 12.70 Bn | 25.18% |
| 4 | Merck | 367.41 Bn | 321.79 Bn | 12.21 Bn | -4.11% |
| 5 | Novartis Ag | 297.66 Bn | 261.65 Bn | 11.24 Bn | 29.63% |
| 6 | Astrazeneca | 261.30 Bn | 234.99 Bn | 12.86 Bn | 18.19% |
| 7 | Amgen | 236.04 Bn | 191.44 Bn | 7.24 Bn | 27.53% |
| 8 | Gilead Sciences | 190.96 Bn | 165.16 Bn | 6.22 Bn | -131.41% |
| 9 | Pfizer | 169.89 Bn | 116.53 Bn | 10.94 Bn | -4.34% |
| 10 | Immucell | 94.27 Mn | 71.72 Mn | 2.44 Mn | 26.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.17% |
| Dec 31, 2025 | -37.32% |
| Sep 30, 2025 | -2.46% |
| Jun 30, 2025 | 7.82% |
| Mar 31, 2025 | 17.96% |
| Dec 31, 2024 | 6.72% |
| Sep 30, 2024 | -11.65% |
| Jun 30, 2024 | -27.96% |
| Mar 31, 2024 | -6.01% |
| Sep 30, 2023 | -17.41% |
| Jun 30, 2023 | -39.01% |
| Mar 31, 2023 | -67.13% |
| Dec 31, 2022 | -42.61% |
| Sep 30, 2022 | -13.58% |
| Jun 30, 2022 | -17.69% |
| Mar 31, 2022 | 8.57% |
| Dec 31, 2021 | 1.38% |
| Sep 30, 2021 | 3.03% |
| Jun 30, 2021 | 3.11% |
| Mar 31, 2021 | -10.74% |
API Access
Immucell EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "ICCC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();